Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.

Therabody executives worried about running out of funds can stop aiming their massage guns at the stress tension in their own shoulders.

On Tuesday, the makers of the Theragun scored a $165 million funding round, according to reporting from The New York Times, led by private equity firm North Castle Partners. Presumably, all the knotty details have been worked out.

Theragun rode the home-wellness boom during the early pandemic when suddenly there was no choice but to workout at home (as Peloton can attest). And with gyms and massage parlors closed, fitness freaks also needed to find a new way to treat their at-home aches and pains.

The Theragun became the weapon of choice, driving Therabody to $224 million in revenue in 2020 and $396 million in 2021. The financing, which comes at an undisclosed valuation, arrives just as the company prepares to pull the trigger on a handful of new products and services:

Theragun Control: Theragun can't shoot down copycats fast enough. The company has already reached settlements with over 15 companies over allegations of infringing on intellectual property, NYT reports, and cheap competitors and knockoffs of its $400 marquee Theragun Elite model continue to hit the market. But from an IP perspective, not all of them have the right to massage bare arms.

Market-beating stocks from our award-winning analyst team.

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

Making the world smarter, happier, and richer.

Market data powered by Xignite.